KR20240166574A - 점액점착 및 바이러스 결합 특성을 가진 2중 기능성 펩타이드 - Google Patents

점액점착 및 바이러스 결합 특성을 가진 2중 기능성 펩타이드 Download PDF

Info

Publication number
KR20240166574A
KR20240166574A KR1020247036397A KR20247036397A KR20240166574A KR 20240166574 A KR20240166574 A KR 20240166574A KR 1020247036397 A KR1020247036397 A KR 1020247036397A KR 20247036397 A KR20247036397 A KR 20247036397A KR 20240166574 A KR20240166574 A KR 20240166574A
Authority
KR
South Korea
Prior art keywords
seq
peptide
binding moiety
virus
mucin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036397A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 라우스터
로빈 디엔
타티아나 포볼로츠키
마르쿠스 바르두아
크리스티안 헤켄베르거
세바스티안 플로레스
얀 말리
안드레아스 허먼
Original Assignee
프라이 유니베르시탯 베를린
포슝스베어분드 베를린 에.베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프라이 유니베르시탯 베를린, 포슝스베어분드 베를린 에.베 filed Critical 프라이 유니베르시탯 베를린
Publication of KR20240166574A publication Critical patent/KR20240166574A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247036397A 2022-04-01 2023-03-31 점액점착 및 바이러스 결합 특성을 가진 2중 기능성 펩타이드 Pending KR20240166574A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166380.0 2022-04-01
EP22166380 2022-04-01
PCT/EP2023/058432 WO2023187142A1 (en) 2022-04-01 2023-03-31 Bifunctional peptide with mucoadhesive and virus binding properties

Publications (1)

Publication Number Publication Date
KR20240166574A true KR20240166574A (ko) 2024-11-26

Family

ID=81448252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036397A Pending KR20240166574A (ko) 2022-04-01 2023-03-31 점액점착 및 바이러스 결합 특성을 가진 2중 기능성 펩타이드

Country Status (8)

Country Link
US (1) US20250250312A1 (https=)
EP (1) EP4504342B1 (https=)
JP (1) JP2025514630A (https=)
KR (1) KR20240166574A (https=)
CN (1) CN119677782A (https=)
AU (1) AU2023246944A1 (https=)
CA (1) CA3254872A1 (https=)
WO (1) WO2023187142A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4684804A1 (en) 2024-07-26 2026-01-28 Freie Universität Berlin Conjugation product comprising an antigen binding moiety and a mucin binding moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021190980A1 (en) * 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021257781A1 (en) * 2020-06-19 2021-12-23 Vast Sea Biotechnology, Inc. Compositions and methods for treating covid-19

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
Bhatia, Sumati, et al. "Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo." Biomaterials 138 (2017): 22-34.
Braga Emidio, Nayara, et al. "Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite." Journal of Medicinal Chemistry 64.13 (2021): 9484-9495.
Bui, Vuong N., et al. "Pathogenicity of an H5N1 avian influenza virus isolated in Vietnam in 2012 and reliability of conjunctival samples for diagnosis of infection." Virus Research 179 (2014): 125-132.
Caban, Madelyn, et al. "Cross-protective antibodies against common endemic respiratory viruses." Nature Communications 14.1 (2023): 798.
Han, Dong P., Adam Penn-Nicholson, and Michael W. Cho. "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." Virology 350.1 (2006): 15-25.
Hoffmann, Markus, et al. "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor." Cell 181.2 (2020): 271-280.
Hoffmann, Miriam, Nicole L. Snyder, and Laura Hartmann. "Polymers Inspired by Heparin and Heparan Sulfate for Viral Targeting." Macromolecules 55.18 (2022): 7957-7973.
Hoffmann, Werner. "Trefoil factor family (TFF) peptides and their different roles in the mucosal innate immune defense and more: An update." Current Medicinal Chemistry 28.36 (2021): 7387-7399.
Hrebik, Dominik, et al. "ICAM-1 induced rearrangements of capsid and genome prime rhinovirus 14 for activation and uncoating." Proceedings of the National Academy of Sciences 118.19 (2021): e2024251118.
Issmail, Leila, et al. "Prefusion-specific antibody-derived peptides trivalently presented on DNA-nanoscaffolds as an innovative strategy against RSV entry." Frontiers in Virology 2 (2022).
Jarva, Michael A., et al. "Trefoil factors share a lectin activity that defines their role in mucus." Nature Communications 11.1 (2020): 1-9.
Jerabek-Willemsen M., et al. "MicroScale Thermophoresis: Interaction analysis and beyond." Journal of Molecular Structure 1077 (2014): 101-113.
Khan, Abdul Ghafoor, et al. "Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH." Journal of Virology 81.9 (2007): 4625-4632.
Madsen, Anders, et al. "Human antibodies targeting influenza B virus neuraminidase active site are broadly protective." Immunity 53.4 (2020): 852-863.
McLellan, Jason S., et al. "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus." science 342.6158 (2013): 592-598.
Memczak, Henry, et al. "Anti-hemagglutinin antibody derived lead peptides for inhibitors of influenza virus binding." PLoS One 11.7 (2016): e0159074.
Sarto, Carolina, et al. "Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein." Biological Chemistry 403.5-6 (2022): 615-624.
Smith, Thomas J., et al. "Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon." Nature 383.6598 (1996): 350-354.
Thim, L., F. Madsen, and S. S. Poulsen. "Effect of trefoil factors on the viscoelastic properties of mucus gels." European Journal of Clinical Investigation 32.7 (2002): 519-527.
Zhu, Qing, et al. "A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants." Science Translational Medicine 9.388 (2017): eaaj1928.
Zuo, Teng, et al. "Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection." Nature Communications 6.1 (2015): 8855.

Also Published As

Publication number Publication date
WO2023187142A1 (en) 2023-10-05
CN119677782A (zh) 2025-03-21
JP2025514630A (ja) 2025-05-09
AU2023246944A1 (en) 2024-10-10
CA3254872A1 (en) 2023-10-05
EP4504342B1 (en) 2026-04-29
US20250250312A1 (en) 2025-08-07
EP4504342A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
CN101415723B (zh) 具有改良生物学特性的hiv融合抑制肽
JP2010505831A (ja) 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
WO2014154134A1 (zh) 对新型冠状病毒HCoV-EMC 2012感染具有抑制作用的多肽及其应用
CN111675752B (zh) 一种冠状病毒膜融合抑制剂及其药物用途
KR20240166574A (ko) 점액점착 및 바이러스 결합 특성을 가진 2중 기능성 펩타이드
WO2009155789A1 (zh) 抑制hiv感染的多肽及其衍生物
EP3210995B1 (en) Hemagglutinin-binding peptide
US12534514B2 (en) Biological and synthetic molecules inhibiting respiratory syncytial virus infection
JP7854211B2 (ja) ヘマグルチニン結合ペプチド
JP2013071904A (ja) 抗インフルエンザウイルス活性を有するペプチド
EP3423471A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
JP6921002B2 (ja) ペプチド模倣化合物を中和するインフルエンザウイルス
JP2017512760A (ja) 環状アペリン類似体
CN117120459A (zh) 抗感染双环肽配体
CN110234337A (zh) 中和流感病毒的化合物
CN104277113B (zh) 抑制hiv感染的二价多肽
CN108822190B (zh) 多肽及其药物组合物和用途
JP5396111B2 (ja) インフルエンザ治療／予防薬
Patil et al. Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections
Sharma Design, synthesis, characterization, and biological evaluation of peptides targeting infectious diseases: Host-directed therapy against Mycobacterium tuberculosis and Stapled peptide fusion-inhibitors targeting SARS-CoV-2
CN120435304A (zh) Ccr2抑制剂及使用方法
CN120098150A (zh) 一种广谱抗新型冠状病毒的双靶点多肽及其应用
EA039991B1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302